Method for diagnosing spinocerebellar ataxia type 2 and primers therefor

• US 6,251,589 B1
• Filed: 05/18/1998
• Issued: 06/26/2001
• Est. Priority Date: 07/18/1996
• Status: Expired due to Fees

• Current Assignee: SRL Incorporated (H.U. Group Holdings, Inc.)
• Original Assignee: SRL Incorporated (H.U. Group Holdings, Inc.)
• Inventors: Sanpei, Kazuhiro, Tsuji, Shoji
• Primary Examiner(s): Arthur, Lisa B.
• Assistant Examiner(s): Goldberg, Jeanine
• Application Number:
  US09/043,303
• Time in Patent Office: 1,135 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 536/23.1, 536/24.33, 536/24.3
• US Class Current: 435/6.13
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

A method for specifically diagnosing spinocerebellar ataxia type 2 (SCA2) is disclosed. In the method of the present invention, PCR is carried out using a first primer which hybridizes with a part of the nucleotide sequence shown in SEQ ID NO:1, a second primer which hybridizes with a part of the nucleotide sequence shown in SEQ ID NO:3, and a test DNA as a template, and the number of CAG repeats is measured in the amplified PCR product. Since the numbers of CAG repeat in the genes of SCA2 patients are not less than 35 while those of normal individuals are 15 to 24, diagnosis of SCA2 can be carried out by the method of the present invention.

Claims

1. A method for diagnosing spinocerebellar ataxia type 2 in a human nucleic acid sample comprising the steps of:

amplifying said nucleic acid sample with a first primer and a second primer by polymerase chain reaction, wherein said first primer hybridizes to a region of SEQ ID NO;

1 and said second primer hybridizes to a region of SEQ ID NO;

3;

obtaining an amplification product of said nucleic acid sample by said polymerase chain reaction; and

measuring a number of CAG repeats in said amplification product,

wherein a number of 35 or more CAG repeats in said nucleic acid sample is indicative of said spinocerebellar ataxia type 2 and a number of 15-24 CAG repeats in said nucleic acid sample would be negative for spinocerebellar ataxia type 2.

2. The method of claim 1, wherein said first primer has a sequence as in SEQ ID NO:

19.

3. The method of claim 1, wherein said second primer has a sequence as in SEQ ID NO:

20.

4. The method of claim 1, wherein said number of CAG repeats is measured by gel electrophoresis.

5. The method of claim 1, wherein said number of CAG repeats is measured by sequencing said amplification product.

6. The method of claim 1, wherein said number of CAG repeats is measured by hybridizing a probe to said amplification product, wherein said probe has a sequence of SEQ ID NO:

17.

7. The method of claim 1, wherein the nucleic acid sample is a genomic DNA.

8. The method of claim 1, wherein the nucleic acid sample is a cDNA.